Cargando…

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

BACKGROUND: We evaluated the efficacy and safety of single-dose fosaprepitant in combination with intravenous granisetron and dexamethasone. PATIENTS AND METHODS: Patients receiving chemotherapy including cisplatin (≥70 mg/m(2)) were eligible. A total of 347 patients (21% had received cisplatin with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, H., Yoshizawa, H., Yoshimori, K., Katakami, N., Katsumata, N., Kawahara, M., Eguchi, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603438/ https://www.ncbi.nlm.nih.gov/pubmed/23117073 http://dx.doi.org/10.1093/annonc/mds541

Ejemplares similares

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant
por: Olver, Ian N
Publicado: (2008)

Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
por: Ando, Yosuke, et al.
Publicado: (2015)

Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
por: Celio, Luigi, et al.
Publicado: (2013)

Pharmacokinetics of Dexamethasone when Administered with Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting and Differences in Dose-Dependent Antiemetic Effects
por: Shimamoto, Fukutaro, et al.
Publicado: (2021)

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010)

Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives
por: Candelario, Nellowe, et al.
Publicado: (2016)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial(†)
por: Weinstein, C., et al.
Publicado: (2016)

Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin
por: Zhao, Yuanyuan, et al.
Publicado: (2022)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type
por: Weinstein, Cindy, et al.
Publicado: (2020)

Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial
por: Zhang, Zhonghan, et al.
Publicado: (2020)

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)
por: Navari, Rudolph M, et al.
Publicado: (2023)

The Effects of Intravenous Fosaprepitant and Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Neurosurgery Patients: A Prospective, Randomized, Double-Blinded Study
por: Tsutsumi, Yasuo M., et al.
Publicado: (2014)

A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis
por: Murakami, Chiaki, et al.
Publicado: (2017)

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis
por: Xu, Xinglu, et al.
Publicado: (2022)

Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double‐blind, phase III study
por: Yang, L.Q., et al.
Publicado: (2017)

Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
por: Hata, Akito, et al.
Publicado: (2022)

Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy–Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial
por: Yang, Qi, et al.
Publicado: (2023)

Evaluating the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens
por: Fahimi, Fanak, et al.
Publicado: (2011)

Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study
por: Willier, Semjon, et al.
Publicado: (2019)

Comparative Study Between Fosaprepitant and Palonosetron in the Prophylaxis of Postoperative Nausea and Vomiting in Women Undergoing Laparoscopic Cholecystectomy: Prospective, Randomized and Double-Blind Study
por: Braga, Estêvão Luiz Carvalho, et al.
Publicado: (2022)

Cisplatin-Induced Nausea and Vomiting: Effect of Herbal Medicines
por: Shin, Yuchan, et al.
Publicado: (2022)

A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide
por: Matsumoto, Koji, et al.
Publicado: (2020)

Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study
por: Kenward, Hannah, et al.
Publicado: (2017)

Olanzapine 5 mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy
por: Wang, Jun, et al.
Publicado: (2022)

Effective Dose of Ramosetron for Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Patients
por: Lee, Seongheon, et al.
Publicado: (2015)

Low-dose naloxone for prophylaxis of sufentanil-induced choking and postoperative nausea and vomiting
por: Qian, Yiling, et al.
Publicado: (2022)

Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
por: Sugawara, Shunichi, et al.
Publicado: (2019)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy
por: Kumagai, Hozumi, et al.
Publicado: (2018)

Comment on ‘risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy’
por: Tong, Wing H, et al.
Publicado: (2023)

Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)
por: Hata, Akito, et al.
Publicado: (2022)

Postoperative nausea and vomiting
por: Moon, Young Eun
Publicado: (2014)

Different Doses of Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Children Undergoing Strabismus Surgery
por: Bicer, Cihangir, et al.
Publicado: (2012)

Cardiovascular Safety Profile and Clinical Experience With High-Dose Domperidone Therapy for Nausea and Vomiting
por: Ortiz, Arleen, et al.
Publicado: (2015)

Comparison of equipotent doses of Ramosetron, Ondansetron, and sub-hypnotic dose of Propofol for prevention of postoperative nausea and vomiting in laparoscopic cholecystectomy
por: Acharya, Shilpa Amol, et al.
Publicado: (2021)

The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting
por: Coyne, Joseph W.
Publicado: (2016)

Caffeine for the prevention of postoperative nausea and vomiting
por: Steinbrook, Richard A, et al.
Publicado: (2013)

Anticipatory nausea in cyclical vomiting
por: McRonald, Fiona E, et al.
Publicado: (2005)

Nausea in Specific Phobia of Vomiting
por: Höller, Yvonne, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gc3re4rnmd02l7bh2ub7grpk9q